Detalhe da pesquisa
1.
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
Antimicrob Agents Chemother
; 66(1): e0164521, 2022 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34694878
2.
Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
J Infect Dis
; 210(3): 354-62, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24446523
3.
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.
J Infect Dis
; 207(5): 740-8, 2013 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23225901
4.
Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572).
Antimicrob Agents Chemother
; 57(3): 1379-84, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23295935
5.
Sensitive HIV-1 DNA Pol Next-Generation Sequencing for the Characterisation of Archived Antiretroviral Drug Resistance.
Viruses
; 15(9)2023 08 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37766218
6.
Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
HIV Clin Trials
; 11(5): 239-47, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21126954
7.
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
J Pediatric Infect Dis Soc
; 9(2): 159-165, 2020 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-30951600
8.
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Lancet
; 368(9534): 476-82, 2006 Aug 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-16890834
9.
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
Lancet HIV
; 4(12): e536-e546, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-28729158
10.
Fosamprenavir clinical study meta-analysis in ART-naïve subjects: rare occurrence of virologic failure and selection of protease-associated mutations.
HIV Clin Trials
; 7(6): 334-8, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17197380
11.
Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
Antivir Ther
; 20(3): 343-8, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25321146
12.
Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.
Pediatr Infect Dis J
; 23(1): 15-22, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14743040
13.
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
J Acquir Immune Defic Syndr
; 55(1): 49-57, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20431394
14.
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
AIDS
; 23(12): 1547-56, 2009 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-19542866
15.
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
J Acquir Immune Defic Syndr
; 40(4): 422-7, 2005 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16280696